drugset / Trial / NCT00309413
A Clinical Trial on the Antipsychotic Properties of Cannabidiol
Phase 2
Completed
29 enrolled
University of Cologne
Coordinating Centre for Clinical Trials Cologne · collabStanley Medical Research Institute · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-03
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cannabidiol | Other / unclassified | 600 mg | Oral |